{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:44Z","timestamp":1792787864151,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03304-3","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:57:18Z","timestamp":1766012238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Co-delivery of Sorafenib and Venetoclax to Induce Ferroptosis and Apoptosis Mediated Cancer Cell Death using Surface Modified PLGA Nanoparticles"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0012-9401","authenticated-orcid":false,"given":"Dhruv","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6939-9201","authenticated-orcid":false,"given":"Smriti","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8957-8875","authenticated-orcid":false,"given":"Vivek","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-1500","authenticated-orcid":false,"given":"Kaushik","family":"Kuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5435-8807","authenticated-orcid":false,"given":"Pratik","family":"Dhake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9563","authenticated-orcid":false,"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"7782","key":"3304_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"3","key":"3304_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.24064","volume":"124","author":"S Fulda","year":"2009","unstructured":"Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124(3):511\u20135.","journal-title":"Int J Cancer"},{"issue":"5","key":"3304_CR3","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1007\/s11033-019-04958-6","volume":"46","author":"M Panda","year":"2019","unstructured":"Panda M, Biswal BK. Cell signaling and cancer: a mechanistic insight into drug resistance. Mol Biol Rep. 2019;46(5):5645\u201359.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"3304_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679\u201392.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"3304_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"issue":"34","key":"3304_CR6","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798\u2013811.","journal-title":"Oncogene"},{"issue":"6","key":"3304_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1189\/jlb.71.6.907","volume":"71","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907\u201320.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"3304_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"1","key":"3304_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/imr.12533","volume":"277","author":"SJ Dixon","year":"2017","unstructured":"Dixon SJ. Ferroptosis: bug or feature? Immunol Rev. 2017;277(1):150\u20137.","journal-title":"Immunol Rev"},{"issue":"100","key":"3304_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105998","volume":"1","author":"PK Pandey","year":"2024","unstructured":"Pandey PK, Bhorkade S, Jha S, Saren BN, Kuche K, Jain S. Ferroptosis: molecular perspective, cellular influence, cancer manifestation, and therapeutic potentials. J Drug Deliv Sci Technol. 2024;1(100):105998.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"3304_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2007.09.021","volume":"60","author":"HR Kim","year":"2008","unstructured":"Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, et al. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer. 2008;60(1):47\u201356.","journal-title":"Lung Cancer"},{"key":"3304_CR12","doi-asserted-by":"publisher","unstructured":"Shi H, Xiong L, Yan G, Du S, Liu J, Shi Y. Susceptibility of cervical cancer to dihydroartemisinin-induced ferritinophagy-dependent ferroptosis. Front Mol Biosci [Internet]. 2023 Mar 31 [cited 2024 Aug 28];10. Available from: https:\/\/www.frontiersin.org\/journals\/molecular-biosciences\/articles\/https:\/\/doi.org\/10.3389\/fmolb.2023.1156062\/full.","DOI":"10.3389\/fmolb.2023.1156062\/full"},{"issue":"156","key":"3304_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213700","volume":"1","author":"K Kuche","year":"2024","unstructured":"Kuche K, Yadav V, Patel M, Chaudhari D, Date T, Jain S. Enhancing anti-cancer potential by delivering synergistic drug combinations via phenylboronic acid modified PLGA nanoparticles through ferroptosis-based therapy. Biomaterials Advances. 2024;1(156):213700.","journal-title":"Biomaterials Advances"},{"issue":"253","key":"3304_CR14","doi-asserted-by":"publisher","first-page":"127254","DOI":"10.1016\/j.ijbiomac.2023.127254","volume":"31","author":"K Kuche","year":"2023","unstructured":"Kuche K, Yadav V, Dharshini M, Ghadi R, Chaudhari D, Date T, et al. Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin. Int J Biol Macromol. 2023;31(253):127254.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"3304_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1208\/s12249-023-02639-z","volume":"24","author":"K Kuche","year":"2023","unstructured":"Kuche K, Yadav V, Patel M, Ghadi R, Jain S. Exploring sorafenib and simvastatin combination for ferroptosis-induced cancer treatment: cytotoxicity screening, in vivo efficacy, and safety assessment. AAPS PharmSciTech. 2023;24(7):180.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3304_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1021\/acsnano.8b05602","volume":"13","author":"W Bao","year":"2019","unstructured":"Bao W, Liu X, Lv Y, Lu GH, Li F, Zhang F, et al. Nanolongan with multiple on-demand conversions for ferroptosis-apoptosis combined anticancer therapy. ACS Nano. 2019;13(1):260\u201373.","journal-title":"ACS Nano"},{"issue":"39","key":"3304_CR17","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.nantod.2021.101212","volume":"1","author":"L Zhou","year":"2021","unstructured":"Zhou L, Dong C, Ding L, Feng W, Yu L, Cui X, et al. Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy. Nano Today. 2021;1(39):101212.","journal-title":"Nano Today"},{"issue":"648","key":"3304_CR18","doi-asserted-by":"publisher","first-page":"123570","DOI":"10.1016\/j.ijpharm.2023.123570","volume":"15","author":"R Ghadi","year":"2023","unstructured":"Ghadi R, Pandey PK, Gabhale A, Wadikar A, Dharshini M, Kuche K, et al. Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer. Int J Pharm. 2023;15(648):123570.","journal-title":"Int J Pharm"},{"issue":"2","key":"3304_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"3304_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324\u201337.","journal-title":"Oncogene"},{"key":"3304_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine\u2013glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.","journal-title":"Elife"},{"key":"3304_CR22","doi-asserted-by":"publisher","first-page":"175913","DOI":"10.1016\/j.ejphar.2023.175913","volume":"955","author":"Q Li","year":"2023","unstructured":"Li Q, Chen K, Zhang T, Jiang D, Chen L, Jiang J, et al. Understanding sorafenib-induced ferroptosis and resistance mechanisms: implications for cancer therapy. Eur J Pharmacol. 2023;955:175913.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"3304_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/biology12101337","volume":"12","author":"X Xu","year":"2023","unstructured":"Xu X, Ma W, Qiu G, Xuan L, He C, Zhang T, et al. Venetoclax overcomes sorafenib resistance in acute myeloid leukemia by targeting BCL2. Biology. 2023;12(10):1337.","journal-title":"Biology"},{"issue":"3","key":"3304_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2020003429","volume":"5","author":"BS Moses","year":"2021","unstructured":"Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, et al. Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Adv. 2021;5(3):711\u201324.","journal-title":"Blood Adv"},{"issue":"2","key":"3304_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13738","volume":"295","author":"S Yu","year":"2024","unstructured":"Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, et al. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: a multicenter phase 2 study. J Intern Med. 2024;295(2):216\u201328.","journal-title":"J Intern Med"},{"issue":"4","key":"3304_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41409-018-0347-6","volume":"54","author":"NM Moukalled","year":"2019","unstructured":"Moukalled NM, El Darsa H, Haibe Y, Massoud R, Kanj SS, Mahfouz R, et al. Feasibility of venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Bone Marrow Transplant. 2019;54(4):620\u20134.","journal-title":"Bone Marrow Transplant"},{"issue":"132","key":"3304_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1182\/blood-2018-175","volume":"29","author":"H Zhang","year":"2018","unstructured":"Zhang H, Wilmot B, Bottomly D, Kurtz SE, Eide CA, Damnernsawad A, et al. Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. Blood. 2018;29(132):175.","journal-title":"Blood"},{"issue":"18","key":"3304_CR28","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.2174\/1871520623666230815143303","volume":"23","author":"Y Tang","year":"2023","unstructured":"Tang Y, Song T, Gao L, Mao F. Venetoclax synergizes sunitinib in renal cell carcincoma through inhibition of Bcl-2. Anticancer Agents Med Chem. 2023;23(18):2027\u201334.","journal-title":"Anticancer Agents Med Chem"},{"key":"3304_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mc.70017","author":"L Zhu","year":"2025","unstructured":"Zhu L, Wang W, Dong Y, Han X, Zhang W, Zhang Z, et al. Venetoclax synergizes with regorafenib for colorectal cancer by targeting BCL\u20102. Mol Carcinog. 2025. https:\/\/doi.org\/10.1002\/mc.70017.","journal-title":"Mol Carcinog"},{"issue":"4","key":"3304_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"MT Manzari","year":"2021","unstructured":"Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351\u201370.","journal-title":"Nat Rev Mater"},{"issue":"3","key":"3304_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","volume":"63","author":"S Acharya","year":"2011","unstructured":"Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170\u201383.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3304_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jconrel.2008.09.086","volume":"133","author":"F Danhier","year":"2009","unstructured":"Danhier F, Lecouturier N, Vroman B, J\u00e9r\u00f4me C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11\u20137.","journal-title":"J Control Release"},{"key":"3304_CR33","doi-asserted-by":"crossref","unstructured":"Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, et al. PEGylated PLGA Nanoparticles for the Improved Delivery of Doxorubicin. In: Nanomedicine in Cancer. Jenny Stanford Publishing; 2017.","DOI":"10.1201\/b22358-23"},{"issue":"11","key":"3304_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","volume":"13","author":"M Karimi","year":"2016","unstructured":"Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609\u201323.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3304_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40199-015-0107-8","volume":"23","author":"M Esfandyari-Manesh","year":"2015","unstructured":"Esfandyari-Manesh M, Mostafavi SH, Majidi RF, Koopaei MN, Ravari NS, Amini M, et al. Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles. DARU J Pharm Sci. 2015;23(1):28.","journal-title":"DARU J Pharm Sci"},{"issue":"3","key":"3304_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2004.07.028","volume":"100","author":"KI Ogawara","year":"2004","unstructured":"Ogawara KI, Furumoto K, Nagayama S, Minato K, Higaki K, Kai T, et al. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J Control Release. 2004;100(3):451\u20135.","journal-title":"J Control Release"},{"issue":"4","key":"3304_CR37","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1021\/nn405830g","volume":"8","author":"GM Mortimer","year":"2014","unstructured":"Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano. 2014;8(4):3357\u201366.","journal-title":"ACS Nano"},{"issue":"49","key":"3304_CR38","doi-asserted-by":"publisher","first-page":"14017","DOI":"10.1021\/jp502624n","volume":"118","author":"CC Fleischer","year":"2014","unstructured":"Fleischer CC, Payne CK. Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles. J Phys Chem B. 2014;118(49):14017\u201326.","journal-title":"J Phys Chem B"},{"issue":"180","key":"3304_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.biomaterials.2018.07.024","volume":"1","author":"H Hyun","year":"2018","unstructured":"Hyun H, Park J, Willis K, Park JE, Lyle LT, Lee W, et al. Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. Biomaterials. 2018;1(180):206\u201324.","journal-title":"Biomaterials"},{"issue":"9","key":"3304_CR40","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1021\/cr400407a","volume":"114","author":"Y Liu","year":"2014","unstructured":"Liu Y, Ai K, Lu L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem Rev. 2014;114(9):5057\u2013115.","journal-title":"Chem Rev"},{"issue":"22","key":"3304_CR41","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1002\/adfm.201201156","volume":"22","author":"S Hong","year":"2012","unstructured":"Hong S, Na YS, Choi S, Song IT, Kim WY, Lee H. Non-covalent self-assembly and covalent polymerization co-contribute to polydopamine formation. Adv Funct Mater. 2012;22(22):4711\u20137.","journal-title":"Adv Funct Mater"},{"issue":"4","key":"3304_CR42","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1021\/mp200243k","volume":"8","author":"S Aryal","year":"2011","unstructured":"Aryal S, Hu CMJ, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm. 2011;8(4):1401\u20137.","journal-title":"Mol Pharm"},{"issue":"8","key":"3304_CR43","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C9RA10857B","volume":"10","author":"K Hern\u00e1ndez-Giottonini","year":"2020","unstructured":"Hern\u00e1ndez-Giottonini K, Rodr\u00edguez-C\u00f3rdova R, Guti\u00e9rrez-Valenzuela C, Pe\u00f1u\u00f1uri-Miranda O, Zavala-Rivera P, Guerrero-Germ\u00e1n P, et al. PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. RSC Adv. 2020;10(8):4218\u201331.","journal-title":"RSC Adv"},{"issue":"1","key":"3304_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijpharm.2018.06.025","volume":"547","author":"Y Lv","year":"2018","unstructured":"Lv Y, He H, Qi J, Lu Y, Zhao W, Dong X, et al. Visual validation of the measurement of entrapment efficiency of drug nanocarriers. Int J Pharm. 2018;547(1):395\u2013403.","journal-title":"Int J Pharm"},{"issue":"4","key":"3304_CR45","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1021\/nn405809c","volume":"8","author":"J Park","year":"2014","unstructured":"Park J, Brust TF, Lee HJ, Lee SC, Watts VJ, Yeo Y. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano. 2014;8(4):3347\u201356.","journal-title":"ACS Nano"},{"issue":"15","key":"3304_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122196","volume":"338","author":"R Sharma","year":"2024","unstructured":"Sharma R, Yadav V, Jha S, Dighe S, Jain S. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer. Carbohydr Polym. 2024;338(15):122196.","journal-title":"Carbohydr Polym"},{"key":"3304_CR47","unstructured":"\u201cStep Wise Freeze Drying Process For Improving Stability Of Nano Drug [Internet]. [cited 2025 June 30]. Available from: https:\/\/www.quickcompany.in\/patents\/a-universal-step-wise-freeze-drying-process-for-lyophilization-of-pharmaceutical-products."},{"issue":"6","key":"3304_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1208\/s12249-025-03168-7","volume":"26","author":"S Jain","year":"2025","unstructured":"Jain S, Mali S, Akhtar J, Dora CP, Mahajan RR. Phospholipid complex-based topical gel for codelivery of Erlotinib and Methotrexate in Psoriasis. AAPS PharmSciTech. 2025;26(6):172.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"3304_CR49","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s13346-022-01273-9","volume":"13","author":"D Chaudhari","year":"2023","unstructured":"Chaudhari D, Kuche K, Yadav V, Ghadi R, Date T, Bhargavi N, et al. Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer. Drug Deliv Transl Res. 2023;13(4):1074\u201387.","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"3304_CR50","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1021\/acsbiomaterials.2c00594","volume":"8","author":"D Chaudhari","year":"2022","unstructured":"Chaudhari D, Katari O, Ghadi R, Kuche K, Date T, Bhargavi N, et al. Unfolding the potency of adenosine in targeting triple negative breast cancer via paclitaxel-incorporated pH-responsive stealth liposomes. ACS Biomater Sci Eng. 2022;8(8):3473\u201384.","journal-title":"ACS Biomater Sci Eng"},{"issue":"6","key":"3304_CR51","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1021\/acsbiomaterials.1c01582","volume":"8","author":"T Date","year":"2022","unstructured":"Date T, Kuche K, Chaudhari D, Ghadi R, Sahel DK, Chitkara D, et al. Hitting multiple cellular targets in triple-negative breast cancer using dual-action Cisplatin(IV) prodrugs for safer synergistic chemotherapy. ACS Biomater Sci Eng. 2022;8(6):2349\u201362.","journal-title":"ACS Biomater Sci Eng"},{"issue":"1","key":"3304_CR52","doi-asserted-by":"publisher","first-page":"213822","DOI":"10.1016\/j.bioadv.2024.213822","volume":"159","author":"R Ghadi","year":"2024","unstructured":"Ghadi R, Kuche K, Date T, Nallamothu B, Chaudhari D, Jain S. Unlocking apoptosis in triple negative breast cancer: harnessing \u201cglutamine trap\u201d to amplify the efficacy of lapatinib-loaded mixed micelles. Biomaterials Advances. 2024;159(1):213822.","journal-title":"Biomaterials Advances"},{"issue":"4","key":"3304_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/156720106778559074","volume":"3","author":"B Malaekeh-Nikouei","year":"2006","unstructured":"Malaekeh-Nikouei B, SajadiTabassi SA, Jaafari MR. The effect of different grades of PLGA on characteristics of microspheres encapsulated with cyclosporine A. Curr Drug Deliv. 2006;3(4):343\u20139.","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"3304_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijpharm.2007.08.034","volume":"350","author":"X Song","year":"2008","unstructured":"Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q, et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm. 2008;350(1):320\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"3304_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41120-022-00060-7","volume":"8","author":"M Alvi","year":"2022","unstructured":"Alvi M, Yaqoob A, Rehman K, Shoaib SM, Akash MSH. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022;8(1):12.","journal-title":"AAPS Open"},{"issue":"2","key":"3304_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijpharm.2006.11.061","volume":"336","author":"A Budhian","year":"2007","unstructured":"Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336(2):367\u201375.","journal-title":"Int J Pharm"},{"key":"3304_CR57","doi-asserted-by":"publisher","unstructured":"Miladi K, Sfar S, Fessi H, Elaissari A. Nanoprecipitation Process: From Particle Preparation to In Vivo Applications. In: Vauthier C, Ponchel G, editors. Polymer Nanoparticles for Nanomedicines: A Guide for their Design, Preparation and Development [Internet]. Cham: Springer International Publishing; 2016 [cited 2024 Sept 11]. p. 17\u201353. Available from: https:\/\/doi.org\/10.1007\/978-3-319-41421-8_2.","DOI":"10.1007\/978-3-319-41421-8_2"},{"issue":"9","key":"3304_CR58","doi-asserted-by":"publisher","first-page":"101697","DOI":"10.1016\/j.jsps.2023.101697","volume":"31","author":"M Sakhi","year":"2023","unstructured":"Sakhi M, Khan A, Khan I, Ahmad Khan S, Irum Khan S, Ali Khattak M, et al. Effect of polymeric stabilizers on the size and stability of PLGA paclitaxel nanoparticles. Saudi Pharm J. 2023;31(9):101697.","journal-title":"Saudi Pharm J"},{"issue":"4","key":"3304_CR59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1081\/DDC-100102197","volume":"25","author":"JM Barichello","year":"1999","unstructured":"Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm. 1999;25(4):471\u20136.","journal-title":"Drug Dev Ind Pharm"},{"key":"3304_CR60","doi-asserted-by":"publisher","unstructured":"Han FY, Thurecht KJ, Whittaker AK, Smith MT. Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Front Pharmacol [Internet]. 2016 June 28 [cited 2025 July 4];7. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2016.00185\/full.","DOI":"10.3389\/fphar.2016.00185\/full"},{"issue":"8","key":"3304_CR61","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1021\/acs.biomac.3c00363","volume":"24","author":"E Argitekin","year":"2023","unstructured":"Argitekin E, Ersoz-Gulseven E, Cakan-Akdogan G, Akdogan Y. Dopamine-conjugated bovine serum albumin nanoparticles containing pH-responsive catechol-V(III) coordination for in vitro and in vivo drug delivery. Biomacromolecules. 2023;24(8):3603\u201318.","journal-title":"Biomacromolecules"},{"key":"3304_CR62","doi-asserted-by":"publisher","first-page":"104759","DOI":"10.1016\/j.jddst.2023.104759","volume":"87","author":"H Li","year":"2023","unstructured":"Li H, He E, Wang Y, Fu J, Liu T, Gou R, et al. Albumin-stabilized polydopamine nanoparticles for chemo-photothermal synergistic therapy of melanoma. J Drug Deliv Sci Technol. 2023;87:104759.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"3304_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s11671-017-1853-y","volume":"12","author":"M Kaasalainen","year":"2017","unstructured":"Kaasalainen M, Aseyev V, von Haartman E, Karaman D\u015e, M\u00e4kil\u00e4 E, Tenhu H, et al. Size, stability, and porosity of mesoporous nanoparticles characterized with light scattering. Nanoscale Res Lett. 2017;12(1):74.","journal-title":"Nanoscale Res Lett"},{"issue":"11","key":"3304_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11051-018-4387-z","volume":"20","author":"LM Gaspar","year":"2018","unstructured":"Gaspar LM, D\u00f3rea AC, Droppa-Almeida D, de M\u00e9lo Silva IS, Montoro FE, Alves LL, et al. Development and characterization of PLGA nanoparticles containing antibiotics. J Nanopart Res. 2018;20(11):289.","journal-title":"J Nanopart Res"},{"issue":"10","key":"3304_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/gels8100679","volume":"8","author":"N Mehwish","year":"2022","unstructured":"Mehwish N, Xu M, Zaeem M, Lee BH. Mussel-inspired surface functionalization of porous albumin cryogels supporting synergistic antibacterial\/antioxidant activity and bone-like apatite formation. Gels. 2022;8(10):679.","journal-title":"Gels"},{"issue":"10","key":"3304_CR66","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s10856-013-4994-2","volume":"24","author":"CC Ho","year":"2013","unstructured":"Ho CC, Ding SJ. The pH-controlled nanoparticles size of polydopamine for anti-cancer drug delivery. J Mater Sci Mater Med. 2013;24(10):2381\u201390.","journal-title":"J Mater Sci Mater Med"},{"key":"3304_CR67","doi-asserted-by":"publisher","unstructured":"Xi J, Da L, Yang C, Chen R, Gao L, Fan L, et al. Mn2+-coordinated PDA@DOX\/PLGA nanoparticles as a smart theranostic agent for synergistic chemo-photothermal tumor therapy. International Journal of Nanomedicine [Internet]. 2017 Apr 24 [cited 2025 Feb 8]; Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.2147\/IJN.S132270.","DOI":"10.2147\/IJN.S132270"},{"issue":"20","key":"3304_CR68","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1039\/C5TB00200A","volume":"3","author":"J Xi","year":"2015","unstructured":"Xi J, Qian X, Qian K, Zhang W, He W, Chen Y, et al. Au nanoparticle-coated, PLGA-based hybrid capsules for combined ultrasound imaging and HIFU therapy. J Mater Chem B. 2015;3(20):4213\u201320.","journal-title":"J Mater Chem B"},{"issue":"13","key":"3304_CR69","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1021\/acs.analchem.5b01451","volume":"87","author":"S Li","year":"2015","unstructured":"Li S, Peng Z, Leblanc RM. Method To Determine Protein Concentration in the Protein-Nanoparticle Conjugates Aqueous Solution Using Circular Dichroism Spectroscopy. Anal Chem. 2015;87(13):6455\u20139.","journal-title":"Anal Chem"},{"issue":"7","key":"3304_CR70","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1208\/s12249-022-02406-6","volume":"23","author":"MR Donthi","year":"2022","unstructured":"Donthi MR, Munnangi SR, Krishna KV, Marathe SA, Saha RN, Singhvi G, et al. Formulating ternary inclusion complex of Sorafenib Tosylate using \u03b2-cyclodextrin and hydrophilic polymers: physicochemical characterization and in vitro assessment. AAPS PharmSciTech. 2022;23(7):254.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3304_CR71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.colsurfb.2010.05.027","volume":"80","author":"G Mohammadi","year":"2010","unstructured":"Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M, et al. Development of azithromycin\u2013PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf, B. 2010;80(1):34\u20139.","journal-title":"Colloids Surf, B"},{"key":"3304_CR72","first-page":"68","volume":"29","author":"S Nangare","year":"2021","unstructured":"Nangare S, Powar T, Hajare A, Jarag R. Development and evaluation of lyophilized methotrexate nanosuspension using quality by design approach. Acta Chim Slov. 2021;29:68.","journal-title":"Acta Chim Slov"},{"issue":"9","key":"3304_CR73","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1080\/07391102.2024.2305695","volume":"43","author":"SK Patil","year":"2025","unstructured":"Patil SK, Chary PS, Maddipatla S, Madhavi YV, Singothu S, Bhandari V, et al. Development of venetoclax with 2-hydroxypropyl-beta-cyclodextrin inclusion complex for improved bioavailability. J Biomol Struct Dyn. 2025;43(9):4847\u201364.","journal-title":"J Biomol Struct Dyn"},{"issue":"7","key":"3304_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11070329","volume":"11","author":"P Vass","year":"2019","unstructured":"Vass P, Hirsch E, K\u00f3czi\u00e1n R, D\u00e9muth B, Farkas A, Feh\u00e9r C, et al. Scaled-up production and tableting of grindable electrospun fibers containing a protein-type drug. Pharmaceutics. 2019;11(7):329.","journal-title":"Pharmaceutics"},{"issue":"4","key":"3304_CR75","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/22297928.2021.1934111","volume":"11","author":"SL Neha","year":"2021","unstructured":"Neha SL, Pannu A, Sahoo PK. Development and validation of UV spectroscopic technique for the assessment of dopamine to prepare NLC formulation in the therapy of Parkinson\u2019s disease. Anal Chem Lett. 2021;11(4):553\u201362.","journal-title":"Anal Chem Lett"},{"issue":"8","key":"3304_CR76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/02652048.2023.2264386","volume":"40","author":"SL Neha","year":"2023","unstructured":"Neha SL, Mishra AK, Rani L, Paroha S, Dewangan HK, Sahoo PK. Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug delivery in Parkinson\u2019s disease. J Microencapsul. 2023;40(8):599\u2013612.","journal-title":"J Microencapsul"},{"key":"3304_CR77","doi-asserted-by":"publisher","unstructured":"Rezvantalab S, Drude NI, Moraveji MK, G\u00fcvener N, Koons EK, Shi Y, et al. PLGA-Based Nanoparticles in Cancer Treatment. Front Pharmacol [Internet]. 2018 Nov 2 [cited 2024 Sept 18];9. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2018.01260\/full.","DOI":"10.3389\/fphar.2018.01260\/full"},{"issue":"13","key":"3304_CR78","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1039\/c2jm16831f","volume":"22","author":"L Xie","year":"2012","unstructured":"Xie L, Tong W, Yu D, Xu J, Li J, Gao C. Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery. J Mater Chem. 2012;22(13):6053\u201360.","journal-title":"J Mater Chem"},{"issue":"1","key":"3304_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpharm.2013.12.045","volume":"463","author":"Q Zheng","year":"2014","unstructured":"Zheng Q, Lin T, Wu H, Guo L, Ye P, Hao Y, et al. Mussel-inspired polydopamine coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release. Int J Pharm. 2014;463(1):22\u20136.","journal-title":"Int J Pharm"},{"issue":"219","key":"3304_CR80","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jconrel.2015.08.050","volume":"10","author":"J Du","year":"2015","unstructured":"Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release. 2015;10(219):205\u201314.","journal-title":"J Control Release"},{"issue":"15","key":"3304_CR81","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2217\/nnm-2018-0415","volume":"14","author":"M Zeeshan","year":"2019","unstructured":"Zeeshan M, Ali H, Khan S, Mukhtar M, Khan MI, Arshad M. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease. Nanomedicine. 2019;14(15):1945\u201369.","journal-title":"Nanomedicine"},{"issue":"3","key":"3304_CR82","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171\u201383.","journal-title":"J Control Release"},{"issue":"11","key":"3304_CR83","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11):2195\u2013209.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"3304_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05558-w","volume":"14","author":"FL Xu","year":"2023","unstructured":"Xu FL, Wu XH, Chen C, Wang K, Huang LY, Xia J, et al. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. Cell Death Dis. 2023;14(1):1\u201314.","journal-title":"Cell Death Dis."},{"issue":"1","key":"3304_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-01800-2","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Wang Y, Tan J, Li Y, Yang P, Liu X, et al. Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway. Cell Death Discov. 2024;10(1):1\u201310.","journal-title":"Cell Death Discov"},{"key":"3304_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2014.03.013","volume":"190","author":"F Kratz","year":"2014","unstructured":"Kratz F. A clinical update of using albumin as a drug vehicle \u2014 a commentary. J Control Release. 2014;190:331\u20136.","journal-title":"J Control Release"},{"issue":"534","key":"3304_CR87","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.bbrc.2020.10.083","volume":"1","author":"Y Li","year":"2021","unstructured":"Li Y, Xia J, Shao F, Zhou Y, Yu J, Wu H, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun. 2021;1(534):877\u201384.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"3304_CR88","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1535-7163.MCT-12-0093","volume":"11","author":"R Coriat","year":"2012","unstructured":"Coriat R, Nicco C, Ch\u00e9reau C, Mir O, Alexandre J, Ropert S, et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012;11(10):2284\u201393.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3304_CR89","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1002\/jcp.28091","volume":"234","author":"LXT Nguyen","year":"2019","unstructured":"Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J Cell Physiol. 2019;234(8):14040\u20139.","journal-title":"J Cell Physiol"},{"issue":"8","key":"3304_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"YE Liu","year":"2023","unstructured":"Liu YE, Lu S, Wu LL, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023;14(8):1\u201312.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3304_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-013-2668-x","volume":"141","author":"C Fumarola","year":"2013","unstructured":"Fumarola C, Caffarra C, La Monica S, Galetti M, Alfieri RR, Cavazzoni A, et al. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK\u2013mTORC1 signaling. Breast Cancer Res Treat. 2013;141(1):67\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"3304_CR92","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9(7):890\u2013909.","journal-title":"Cancer Discov"},{"issue":"2","key":"3304_CR93","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s13346-023-01415-7","volume":"14","author":"A Abhang","year":"2024","unstructured":"Abhang A, Katari O, Ghadi R, Chaudhari D, Jain S. Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management. Drug Deliv Transl Res. 2024;14(2):510\u201323.","journal-title":"Drug Deliv Transl Res"},{"key":"3304_CR94","doi-asserted-by":"crossref","unstructured":"Park K. Injectable, long-acting PLGA formulations_ Analyzing PLGA and understanding microparticle formation. 2019;","DOI":"10.1016\/j.jconrel.2019.05.003"},{"issue":"2","key":"3304_CR95","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322.","journal-title":"J Control Release"},{"issue":"3","key":"3304_CR96","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40242-025-5042-8","volume":"41","author":"Y Wei","year":"2025","unstructured":"Wei Y, Xu F, Xu R, Li X, Yan Y, Long R, et al. Production of PLGA nanoparticles via nanoprecipitation: a systemic study on synthesis conditions. Chem Res Chin Univ. 2025;41(3):643\u201354.","journal-title":"Chem Res Chin Univ"},{"issue":"5","key":"3304_CR97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1208\/s12248-025-01096-9","volume":"27","author":"HSA Ghaly","year":"2025","unstructured":"Ghaly HSA, Seyedasli N, Varamini P. Enhanced nanoprecipitation method for the production of PLGA nanoparticles for oncology applications. AAPS J. 2025;27(5):113.","journal-title":"AAPS J"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03304-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:02:06Z","timestamp":1770318126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03304-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3304"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03304-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that they have no financial or personal affiliations that could have influenced the findings presented in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"58"}}